Badly designed studies may lead to the efficacy of drugs being overestimated and money being wasted on trials that prove fruitless, according to a new study from McGill University in Canada.
Only 11% of drugs that enter clinical trials in humans are ultimately found safe and effective enough to receive regulatory approval.